You are here

Article Text

Article menu
Download PDFPDF
Clinical and epidemiological research
Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies
  1. O Kryštůfková1,
  2. T Vallerskog2,
  3. S Barbasso Helmers2,
  4. H Mann1,
  5. I Půtová1,
  6. J Běláček3,
  7. V Malmström2,
  8. C Trollmo2,
  9. J Vencovský1,
  10. I E Lundberg2
  1. 1
    Institute of Rheumatology, Prague, Czech Republic
  2. 2
    Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden
  3. 3
    Institute of Biophysics and Informatics, First Faculty of Medicine, Charles University, Prague, Czech Republic
  1. O Kryštůfková, Institute of Rheumatology, Prague, Czech Republic, Na Slupi 4, 120 00 Prague 2, Czech Republic; krys{at}revma.cz

Abstract

Objective: To investigate serum levels of B cell activating factor (BAFF) in patients with myositis and correlate these to autoantibody profile, clinical phenotype and treatment.

Methods: BAFF levels in sera from 49 patients with dermatomyositis, 44 with polymyositis, 6 with inclusion body myositis and 30 matched controls were measured by ELISA. Specific autoantibodies were detected by line blot and western blot assays.

Results: Serum levels of BAFF were significantly higher in patients compared to healthy controls (p = 0.003). Patients with anti-Jo-1 autoantibodies had higher BAFF levels than control individuals (p<0.003) or patients without any specific autoantibodies (p<0.05). Patients with dermatomyositis had higher BAFF levels compared to polymyositis (p<0.05). Patients with interstitial lung disease (ILD) had higher BAFF levels than patients without ILD (p<0.05) or controls (p<0.01) but this could be explained by presence of anti-Jo-1 autoantibodies. BAFF levels correlated with serum creatine kinase (CK) (rs = 0.365, p = 0.0005) but not with C-reactive protein (CRP) levels. A negative correlation of BAFF levels with glucocorticoid daily dose for all patients (rs = −0.292, p = 0.003) and with cumulative glucocorticoid doses in early myositis cases (rs = −0.659, p<0.001) was recorded.

Conclusion: Our finding of elevated serum levels of BAFF in patients with myositis with described phenotypes together with the correlations between levels of BAFF and CK and a negative correlation with dose of glucocorticoids, indicate that BAFF could be a potential therapeutic target in such cases.

https://doi.org/10.1136/ard.2008.091405

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Competing interests: None.

    • Funding: This study was supported by the European Community’s FP6, AutoCure LSHB CT-2006-018661 funding, by institutional support MSM 0021620812 from Ministry of Education, Youth and Sports in the Czech Republic and by The Swedish Research Council (03642) K2005-74X-14045-05AK; The Swedish Rheumatism Association, King Gustaf V 80 year Foundation, Karolinska Institutet Foundation.

    • Ethics approval: This study was performed after human ethics approval (Karolinska Hospital Nord, Stockholm and Institute of Rheumatology, Prague) and informed consent was obtained from all contributing individuals.